S&P 500
5.187,70 +6,96 (+0,13%) Nasdaq
16.332,56 -16,69 (-0,10%) NIKKEI 225
38.835,10 +599,03 (+1,57%) Dólar/Euro
1,0757 -0,0016 (-0,15%) Petróleo Brent
83,11 -0,22 (-0,26%) Bitcoin EUR
58.615,99 -426,44 (-0,72%)
Spectral Medical Inc. (SD4.F)
Spectral Medical Inc.
135 The West Mall
Unit 2
Toronto, ON M9C 1C2
Canada
416-626-3233
https://spectraldx.com
Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 29
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Christopher Seto | CEO & Director | 326,2k | N/A | N/A |
| Dr. John A. Kellum M.D. | Chief Medical Officer | 302,55k | N/A | N/A |
Descripción
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Gobierno corporativo
El ISS Governance QualityScore de Spectral Medical Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
